



Registered Office: 3rd Floor, Maker Chambers IV, 222, Nariman Point, Mumbai 400 021
Website: www.ril.com; **e-mail:** investor_relations@ril.com
Tel.: +91 22 2278 5000; **Fax:** +91 22 2278 5111
CIN: L17110MH1973PLC019786

Disclosures with respect to Employees' Stock Option Scheme, 2017 of the Company pursuant to Regulation 14 of the Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014 as on March 31, 2019:

- (A) Relevant disclosures in terms of the 'Guidance note on accounting for employee share-based payments' issued by Institute of Chartered Accountants of India or any other relevant accounting standards as prescribed from time to time**

Members may refer to the audited financial statement prepared as per Indian Accounting Standard (Ind-AS) for the year 2018-19.

- (B) Diluted Earnings Per Share (EPS) pursuant to issue of shares on exercise of options calculated in accordance with Ind-AS 33**

Diluted EPS for the year ended March 31, 2019 is ₹ 55.47 calculated in accordance with Ind-AS 33 (Earnings Per Share). However, diluted EPS is not impacted due to ESOS-2017 as no Option was granted under this Scheme.

- (C) Details related to Employees' Stock Option Scheme, 2017 ("ESOS-2017")**

- i) The description including terms and conditions of ESOS-2017 is summarized as under:

(a)	Date of shareholder's approval	September 1, 2017
(b)	Total number of options approved under ESOS:	6,33,19,568 options. This will be adjusted for any future bonus issue of shares or stock split or consolidation of shares and also may further be adjusted at the discretion of the Board of Directors for any corporate action(s).
(c)	Vesting requirement	Options granted can vest, subject to the minimum vesting period of one year between grant of Options and vesting of Options. The maximum vesting period may extend up to five years from the date of grant of Options or such other period as may be decided by the Board.
(d)	Exercise Price or pricing formula	The Board will determine the exercise price in case of each grant subject to the same being not less than the face value of equity shares of the

		Company and not more than the 'market price' (that is, latest available closing price on a recognised stock exchange, having highest trading volume, on which equity shares of the Company are listed) of the equity shares at the time of grant.
(e)	Maximum term of option granted	Exercise Period would commence from the vesting date and would expire not later seven years from the date of grant of Options or such other period as may be decided by the Board.
(f)	Source of shares (Primary, secondary or combination)	Primary
(g)	Variation in terms of options	None

(ii) Option movement during the year:

(a)	Number of options outstanding at the beginning of year	Nil
(b)	Number of options granted during the year	Nil
(c)	Number of options forfeited / lapsed during the year	Nil
(d)	Number of options vested during the year	Nil
(e)	Number of options exercised during the year	Nil
(f)	Number of shares arising as a result of exercise of options	Nil
(g)	Money realized by exercise of options (₹)	Nil
(h)	Loan repaid by the Trust during the year from exercise price received	Nil
(i)	Number of options outstanding at the end of the year	Nil
(j)	Number of options exercisable at the end of the year	Nil

(iii) Employee wise details of options granted during the year:

- (a) Key managerial personnel and senior managerial personnel – Nil
- (b) Any other employee who receives a grant in any one year of options amounting to 5% or more of options granted during that year – Nil
- (c) Identified employees who were granted options, during any one year, equal to or exceeding 1% of the issued capital (excluding outstanding warrants and conversions) of the Company at the time of grant - Nil

(iv) Method used to account for ESOS-2017:

ESOS-2017 will be accounted using fair value method of accounting.